Answers

#	Group	#	Step	#	Question	Answer
1	Default	1	Inclusion Criteria	1	Click yes if the subject meets the criteria below. Click no if the subject does not meet the criteria below.	
				2	Male or female, age ≥ 50 years of age;	true false
				3	Diagnosis of nAMD and current active lesion (defined as the presence of intraretinal or subretinal fluid as confirmed by Optical Coherence Tomography (OCT); or active choroidal neovascularization (CNV) on Fluorescein Angiography (FA).	true false
				4	All BCVA scores tested at screening using the ETDRS visual acuity chart must be between 73 and 19 letters, (equivalent to Snellen visual acuity of 20/40 to 20/400). Note: Only one eye per subject may be enrolled in this trial. For subjects with both eyes meeting the enrollment criteria, the investigator will select the eye with the worse visual acuity as the test eye, or the eye with the thicker central retinal thickness if the subject has similar visual acuity in both eyes. If there is no significant basis, other factors such as ocular dominance, other ocular diseases, and subject preference may be considered during the selection. The investigator should describe in detail in the subject's medical record the factors considered in the selection of the test eye.	true false
				5	Clear intraocular structures and adequate pupillary dilation at screening to obtain high-quality retinal images for confirmatory diagnosis;	true false

# Group	# Step	#	Question	Answer
		6	The study eye must be a pseudophakic lens (post-cataract surgery status);	true false
		7	Females must not be of childbearing potential (i.e., post-menopausal with last menstrual period more than 12 months prior to enrollment) and must agree not to be an ovum donor;	true false
		8	Males must agree to use effective contraceptive measures if they have sexual intercourse with a woman of childbearing potential and they must agree not to be a sperm donor;	true false
		9	Voluntarily agree to participate in the clinical trial, understand the trial procedures, and be capable of signing the informed consent form before screening; and	true false
		10	Willingness to comply with the study procedures.	true false
	2 Exclusion	1	Click yes if the subject meets the criteria below. Click no if the subject does not meet the criteria below.	
		2	Presence of any ocular disease or history of disease in the study eye other than nAMD that may affect central visual acuity and/or macular detection (e.g., retinal detachment, macular fissure, macular anterior membrane, retinal vein occlusion, etc.);	true false
		3	Presence in the study eye of choroidal neovascular disease due to causes other than AMD (e.g., angioid streak lesion, ocular histoplasmosis, trauma, etc.), or history of macular pathology unrelated to AMD;	true false
		4	Presence in the study eye of scarring, fibrosis, atrophy, dense subcentral hard exudate, or retinal pigment	true false

# Group	# Step	#	Question	Answer
			epithelial tear involving the macula;	
		5	Subretinal hemorrhage accumulating in the center of the macula of the test eye, with an area of hemorrhage ≥ 4 optic disc diameters;	true false
		6	Presence in the study eye of a contraindication to subretinal injection;	true false
		7	History of idiopathic or autoimmune uveitis unrelated to ocular surgery requiring topical corticosteroid or systemic immunosuppressive therapy in any eye prior to screening;	true false
		8	Active ocular infection in any eye (e.g., conjunctivitis, keratitis, scleritis, endophthalmitis, blepharitis, etc.);	true false
		9	Presence of advanced glaucoma or optic neuropathy involving or endangering the central visual field of the test eye or presence of uncontrolled high intraocular pressure in the test eye, defined as an intraocular pressure (IOP) ≥ 25 mm Hg despite treatment with at least 2 antiglaucoma medications;	true false
		10	Spherical equivalent refractive error showing myopia >8 diopters;	true false
		11	History of vitrectomy, scleral buckle or any other retinal surgery or retinal laser in the study eye;	true false
		12	History of glaucoma shunt, trabeculectomy or micro-incision glaucoma surgery in the study;	true false
		13	History of corneal transplant or other corneal surgeries in the study eye;	true false
		14	YAG, SLT, or ALT laser in the eye within 90 days of	true false

# Group	# Step	#	Question	Answer
			screening.	
		15	Unstable or severe cardiovascular disease, accidental or transient cerebrovascular ischemic attack (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), unstable angina pectoris, congestive heart failure, or severe arrhythmia or severe limb ischemia requiring drug therapy,	true false
		16	Uncontrolled hypertension, defined as systolic blood pressure > 160 mmHg and diastolic blood pressure > 100 mmHg after adequate treatment with antihypertensive drug Clinically diagnoses, or Blood pressure meets criteria after two blood pressure readings taken during screening visit,	true false
		17	Cerebrovascular diseases within 12 months prior to screening,	true false
		18	Presence of a history of malignancy within 5 years prior to the first dosing (except for the following neoplastic diseases: skin basal cell carcinoma, cervix in situ carcinoma, breast in situ carcinoma, and skin squamous epithelial cell carcinoma that has been controlled through treatment), or	true false
		19	Those who require systemic and chronic immunosuppressive therapy during the study;	true false
		20	Those with abnormal liver and kidney function: Alanine aminotransferase (ALT) ≥ 2 × upper limit of normal (ULN), Aspartate aminotransferase (AST) ≥ 2 × ULN, Creatinine (Cr) ≥ 3 × ULN, or	true false

# Group	# Step	#	Question	Answer
		21	Abnormal coagulation function (prothrombin time ≥ 3 seconds of the ULN; activated partial thromboplastin time ≥ 10 seconds of the ULN);	true false
		22	Current or prior use of any drug known to be toxic to the retina or optic nerve, including but not limited to chloroquine/hydrochloroquine, deoxylamine, phenothiazine, and ethambutol;	true false
		23	Participation in any other clinical trial within 90 days prior to screening;	true false
		24	Prior receipt of any ocular or systemic gene therapy agent;	true false
		25	Women who are pregnant or breastfeeding; or	true false
		26	Individuals who, in the opinion of the investigator, are unsuitable for participation in the study (e.g., unable to understand and comply with trial requirements or deemed unsuitable by safety concerns);	true false
	3 PI Confirmation	1	Please ensure only the PI completes this section	
		2	The subject has met all inclusion and no exclusion criteria and is eligible to continue participating in this study.	